BioSig raises $945k in PIPE; sells shares and warrants to accredited investors

On April 18, 2023, BioSig Technologies, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited and institutional investors (the “Investors”), pursuant to which the Company sold to the Investors an aggregate of 792,454 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at a purchase price of $1.1925 per share, and warrants (the “Warrants”) to purchase up to 396,227 shares of Common Stock (the “Warrant Shares” and together with the Shares and Warrants, the “Securities”), at an exercise price of $1.13 per share, that will become exercisable six months after the date of issuance and will expire five and one-half years following the date of issuance, in exchange for aggregate consideration of $945,001.40 (the “April PIPE”).